Ruihua Xu, MD
Sun Yat-sen University
9
6
3
N/A
0
5
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+4 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (9)
Research Network
Collaboration Network
Research Areas & Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lin Shen, MD
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
lin shen
Peking University Cancer Hospital & Institute
Shared therapeutic areas:
Worked with same sponsors:
Herui Yao, PhD
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Shared therapeutic areas:
Worked with same sponsors:
Xiuli Zuo, MD,PhD
Qilu Hospital of Shandong University
Shared therapeutic areas:
yuankai shi, MD
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shared therapeutic areas:
Yoon-Koo Kang, MD, PhD
Asan Medical Center
Shared therapeutic areas:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Project Leader
Ono Pharmaceutical Co., Ltd.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (9)
Showing 9 of 9 trials
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Identification of Breath Biomarkers in Esophageal Cancer
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)
All 9 trials loaded